Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

At diagnosis, approximately 40% of patients had tumors within HAR, and 33.7% experienced recurrent tumors near the hippocampus.

Explore diffuse large B-cell lymphoma — symptoms, causes, diagnosis, treatment options, and prevention. Learn about its types ...

People may be a candidate if they: can safely receive high dose chemotherapy and radiation have tumors that are responsive to drugs have relapsed, aggressive lymphoma that still responds to ...

LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...

LUND, SE / ACCESS Newswire / March 20, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...

Learn more about how a research team has successfully used CRISPR gene editing in the fight against cancer.

TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.

Researchers from Tel Aviv University utilized CRISPR to cut a single gene from cancer cells of head and neck tumors—and ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

About Peripheral T Cell Lymphoma Peripheral T cell lymphoma (PTCL ... Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T ...